51
|
The constituent, anti-inflammation, and human neutrophil elastase inhibitory activity of Gnaphalium affine. J Funct Foods 2016. [DOI: 10.1016/j.jff.2016.10.018] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022] Open
|
52
|
Thiede S, Wosniok PR, Herkommer D, Schulz-Fincke AC, Gütschow M, Menche D. Total Synthesis of Leupyrrin B1: A Potent Inhibitor of Human Leukocyte Elastase. Org Lett 2016; 18:3964-7. [DOI: 10.1021/acs.orglett.6b01724] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Affiliation(s)
- Sebastian Thiede
- Kekulé-Institut für
Organische Chemie und Biochemie and ‡Pharmazeutisches
Institut, Universität Bonn, D-53121 Bonn, Germany
| | - Paul R. Wosniok
- Kekulé-Institut für
Organische Chemie und Biochemie and ‡Pharmazeutisches
Institut, Universität Bonn, D-53121 Bonn, Germany
| | - Daniel Herkommer
- Kekulé-Institut für
Organische Chemie und Biochemie and ‡Pharmazeutisches
Institut, Universität Bonn, D-53121 Bonn, Germany
| | - Anna-Christina Schulz-Fincke
- Kekulé-Institut für
Organische Chemie und Biochemie and ‡Pharmazeutisches
Institut, Universität Bonn, D-53121 Bonn, Germany
| | - Michael Gütschow
- Kekulé-Institut für
Organische Chemie und Biochemie and ‡Pharmazeutisches
Institut, Universität Bonn, D-53121 Bonn, Germany
| | - Dirk Menche
- Kekulé-Institut für
Organische Chemie und Biochemie and ‡Pharmazeutisches
Institut, Universität Bonn, D-53121 Bonn, Germany
| |
Collapse
|
53
|
Crocetti L, Schepetkin IA, Ciciani G, Giovannoni MP, Guerrini G, Iacovone A, Khlebnikov AI, Kirpotina LN, Quinn MT, Vergelli C. Synthesis and Pharmacological Evaluation of Indole Derivatives as Deaza Analogues of Potent Human Neutrophil Elastase Inhibitors. Drug Dev Res 2016; 77:285-99. [PMID: 27474878 DOI: 10.1002/ddr.21323] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/28/2016] [Accepted: 07/16/2016] [Indexed: 01/23/2023]
Abstract
Preclinical Research A number of N-benzoylindoles were designed and synthesized as deaza analogs of previously reported potent and selective HNE inhibitors with an indazole scaffold. The new compounds containing substituents and functions that were most active in the previous series were active in the micromolar range (the most potent had IC50 = 3.8 μM) or inactive. These results demonstrated the importance of N-2 in the indazole nucleus. Docking studies performed on several compounds containing the same substituents but with an indole or an indazole scaffold, respectively, highlight interesting aspects concerning the molecule orientation and H-bonding interactions, which could help to explain the lower activity of this new series. Drug Dev Res, 2016. © 2016 Wiley Periodicals, Inc.
Collapse
Affiliation(s)
- Letizia Crocetti
- NEUROFARBA, Sezione di Farmaceutica e Nutraceutica, Università degli Studi di Firenze, Via Ugo Schiff 6, 50019 Sesto Fiorentino, Italy
| | - Igor A Schepetkin
- Department of Microbiology and Immunology, Montana State University, Bozeman, MT, 59717
| | - Giovanna Ciciani
- NEUROFARBA, Sezione di Farmaceutica e Nutraceutica, Università degli Studi di Firenze, Via Ugo Schiff 6, 50019 Sesto Fiorentino, Italy
| | - Maria Paola Giovannoni
- NEUROFARBA, Sezione di Farmaceutica e Nutraceutica, Università degli Studi di Firenze, Via Ugo Schiff 6, 50019 Sesto Fiorentino, Italy
| | - Gabriella Guerrini
- NEUROFARBA, Sezione di Farmaceutica e Nutraceutica, Università degli Studi di Firenze, Via Ugo Schiff 6, 50019 Sesto Fiorentino, Italy
| | - Antonella Iacovone
- NEUROFARBA, Sezione di Farmaceutica e Nutraceutica, Università degli Studi di Firenze, Via Ugo Schiff 6, 50019 Sesto Fiorentino, Italy
| | - Andrei I Khlebnikov
- Department of Biotechnology and Organic Chemistry, Tomsk Polytechnic University, Tomsk 634050, Russia and Department of Chemistry, Altai State Technical University, Barnaul, Russia
| | - Liliya N Kirpotina
- Department of Microbiology and Immunology, Montana State University, Bozeman, MT, 59717
| | - Mark T Quinn
- Department of Microbiology and Immunology, Montana State University, Bozeman, MT, 59717
| | - Claudia Vergelli
- NEUROFARBA, Sezione di Farmaceutica e Nutraceutica, Università degli Studi di Firenze, Via Ugo Schiff 6, 50019 Sesto Fiorentino, Italy
| |
Collapse
|
54
|
Ruivo EFP, Gonçalves LM, Carvalho LAR, Guedes RC, Hofbauer S, Brito JA, Archer M, Moreira R, Lucas SD. Clickable 4-Oxo-β-lactam-Based Selective Probing for Human Neutrophil Elastase Related Proteomes. ChemMedChem 2016; 11:2037-42. [DOI: 10.1002/cmdc.201600258] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/19/2016] [Revised: 06/28/2016] [Indexed: 01/09/2023]
Affiliation(s)
- Eduardo F. P. Ruivo
- Research Institute for Medicines (iMed.ULisboa); Faculty of Pharmacy; Universidade de Lisboa; Av. Prof. Gama Pinto 1649-003 Lisbon Portugal
| | - Lídia M. Gonçalves
- Research Institute for Medicines (iMed.ULisboa); Faculty of Pharmacy; Universidade de Lisboa; Av. Prof. Gama Pinto 1649-003 Lisbon Portugal
| | - Luís A. R. Carvalho
- Research Institute for Medicines (iMed.ULisboa); Faculty of Pharmacy; Universidade de Lisboa; Av. Prof. Gama Pinto 1649-003 Lisbon Portugal
| | - Rita C. Guedes
- Research Institute for Medicines (iMed.ULisboa); Faculty of Pharmacy; Universidade de Lisboa; Av. Prof. Gama Pinto 1649-003 Lisbon Portugal
| | - Stefan Hofbauer
- Instituto de Tecnologia Química e Biológica-António Xavier; Universidade Nova de Lisboa; Avenida da República 2780-157 Oeiras Portugal
- Department for Structural and Computational Biology; Max F. Perutz Laboratories; University of Vienna; 1030 Vienna Austria
| | - José A. Brito
- Instituto de Tecnologia Química e Biológica-António Xavier; Universidade Nova de Lisboa; Avenida da República 2780-157 Oeiras Portugal
| | - Margarida Archer
- Instituto de Tecnologia Química e Biológica-António Xavier; Universidade Nova de Lisboa; Avenida da República 2780-157 Oeiras Portugal
| | - Rui Moreira
- Research Institute for Medicines (iMed.ULisboa); Faculty of Pharmacy; Universidade de Lisboa; Av. Prof. Gama Pinto 1649-003 Lisbon Portugal
| | - Susana D. Lucas
- Research Institute for Medicines (iMed.ULisboa); Faculty of Pharmacy; Universidade de Lisboa; Av. Prof. Gama Pinto 1649-003 Lisbon Portugal
| |
Collapse
|
55
|
Kandregula CAB, Smilin Bell Aseervatham G, Bentley GT, Kandasamy R. Alpha-1 antitrypsin: Associated diseases and therapeutic uses. Clin Chim Acta 2016; 459:109-116. [PMID: 27259467 DOI: 10.1016/j.cca.2016.05.028] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/05/2016] [Revised: 05/27/2016] [Accepted: 05/30/2016] [Indexed: 11/30/2022]
Affiliation(s)
- Chaya A Babu Kandregula
- Laboratory of Pulmonary Medicine, National Facility for Drug Development for Academia, Pharmaceutical & Allied Industries, Department of Pharmaceutical Technology, Centre for Excellence in Nanobio Translational REsearch (CENTRE), Anna University - BIT Campus, Tiruchirappalli, Tamil Nadu 620024, India
| | - G Smilin Bell Aseervatham
- Laboratory of Pulmonary Medicine, National Facility for Drug Development for Academia, Pharmaceutical & Allied Industries, Department of Pharmaceutical Technology, Centre for Excellence in Nanobio Translational REsearch (CENTRE), Anna University - BIT Campus, Tiruchirappalli, Tamil Nadu 620024, India
| | - Gary T Bentley
- Department of Internal Medicine, Morsani College of Medicine, Tampa, FL 33612, USA
| | - Ruckmani Kandasamy
- Laboratory of Pulmonary Medicine, National Facility for Drug Development for Academia, Pharmaceutical & Allied Industries, Department of Pharmaceutical Technology, Centre for Excellence in Nanobio Translational REsearch (CENTRE), Anna University - BIT Campus, Tiruchirappalli, Tamil Nadu 620024, India.
| |
Collapse
|
56
|
Craciun I, Fenner AM, Kerns RJ. N-Arylacyl O-sulfonated aminoglycosides as novel inhibitors of human neutrophil elastase, cathepsin G and proteinase 3. Glycobiology 2016; 26:701-709. [PMID: 26850997 DOI: 10.1093/glycob/cww011] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/04/2015] [Accepted: 01/23/2016] [Indexed: 12/14/2022] Open
Abstract
The balance between neutrophil serine proteases (NSPs) and protease inhibitors (PIs) in the lung is a critical determinant for a number of chronic inflammatory lung diseases such as chronic obstructive pulmonary disease, cystic fibrosis and acute lung injury. During activation at inflammatory sites, excessive release of NSPs such as human neutrophil elastase (HNE), proteinase 3 (Pr3) and cathepsin G (CatG), leads to destruction of the lung matrix and continued propagation of acute inflammation. Under normal conditions, PIs counteract these effects by inactivating NSPs; however, in chronic inflammatory lung diseases, there are insufficient amounts of PIs to mitigate damage. Therapeutic strategies are needed to modulate excessive NSP activity for the clinical management of chronic inflammatory lung diseases. In the study reported here, a panel of N-arylacyl O-sulfonated aminoglycosides was screened to identify inhibitors of the NSPs. Dose-dependent inhibitors for each individual serine protease were identified. Select compounds were found to inhibit multiple NSPs, including one lead structure that is shown to inhibit all three NSPs. Two lead compounds identified during the screen for each individual NSP were further characterized as partial mixed inhibitors of CatG. Concentration-dependent inhibition of protease-mediated detachment of lung epithelial cells is demonstrated.
Collapse
Affiliation(s)
- Ioana Craciun
- Division of Medicinal and Natural Products Chemistry, Department of Pharmaceutical Sciences and Experimental Pharmaceutics, University of Iowa College of Pharmacy, Iowa City, IA 52242, USA
| | - Amanda M Fenner
- Division of Medicinal and Natural Products Chemistry, Department of Pharmaceutical Sciences and Experimental Pharmaceutics, University of Iowa College of Pharmacy, Iowa City, IA 52242, USA
| | - Robert J Kerns
- Division of Medicinal and Natural Products Chemistry, Department of Pharmaceutical Sciences and Experimental Pharmaceutics, University of Iowa College of Pharmacy, Iowa City, IA 52242, USA
| |
Collapse
|
57
|
Nurwidya F, Damayanti T, Yunus F. The Role of Innate and Adaptive Immune Cells in the Immunopathogenesis of Chronic Obstructive Pulmonary Disease. Tuberc Respir Dis (Seoul) 2016; 79:5-13. [PMID: 26770229 PMCID: PMC4701795 DOI: 10.4046/trd.2016.79.1.5] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/06/2015] [Revised: 09/01/2015] [Accepted: 10/12/2015] [Indexed: 01/19/2023] Open
Abstract
Chronic obstructive pulmonary disease (COPD) is a chronic and progressive inflammatory disease of the airways and lungs that results in limitations of continuous airflow and is caused by exposure to noxious gasses and particles. A major cause of morbidity and mortality in adults, COPD is a complex disease pathologically mediated by many inflammatory pathways. Macrophages, neutrophils, dendritic cells, and CD8+ T-lymphocytes are the key inflammatory cells involved in COPD. Recently, the non-coding small RNA, micro-RNA, have also been intensively investigated and evidence suggest that it plays a role in the pathogenesis of COPD. Here, we discuss the accumulated evidence that has since revealed the role of each inflammatory cell and their involvement in the immunopathogenesis of COPD. Mechanisms of steroid resistance in COPD will also be briefly discussed.
Collapse
Affiliation(s)
- Fariz Nurwidya
- Department of Respiratory Medicine, Persahabatan General Hospital, University of Indonesia Faculty of Medicine, Jakarta, Indonesia
| | - Triya Damayanti
- Department of Respiratory Medicine, Persahabatan General Hospital, University of Indonesia Faculty of Medicine, Jakarta, Indonesia
| | - Faisal Yunus
- Department of Respiratory Medicine, Persahabatan General Hospital, University of Indonesia Faculty of Medicine, Jakarta, Indonesia
| |
Collapse
|
58
|
Luo D, Chen QY, Luesch H. Total Synthesis of the Potent Marine-Derived Elastase Inhibitor Lyngbyastatin 7 and in Vitro Biological Evaluation in Model Systems for Pulmonary Diseases. J Org Chem 2015; 81:532-44. [PMID: 26709602 DOI: 10.1021/acs.joc.5b02386] [Citation(s) in RCA: 26] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
Lyngbyastatin 7 (1) is a marine cyanobacteria-derived lariat-type cyclic depsipeptide of which the macrocyclic core possesses modified amino acids, including a featured 3-amino-6-hydroxy-2-piperidone (Ahp) moiety and a (Z)-2-amino-2-butenoic acid (Abu) moiety. The first total synthesis of 1 was successfully established via 31 steps, and the conditions of several crucial steps were optimized to ensure smooth operations. The previously reported structural assignment and elastase inhibitory activity of the isolated natural product were confirmed. According to the extensive in vitro biological evaluation, compound 1 displayed low nanomolar IC50 in blocking elastase activity and strong ability in protecting bronchial epithelial cells against elastase-induced antiproliferation and abrogating the elastase-triggered induction of pro-inflammatory cytokine expression. Its overall performance was superior over sivelestat, the only approved small molecule drug targeting elastase, which indicated its potential in developing as a pharmacotherapeutic against elastase-mediated pathologies. The success in total synthesis, designed with a novel convergent strategy, not only overcame the supply issue for thorough preclinical studies but also paved the way for convenient synthesis of analogues with improved potency and druglike properties.
Collapse
Affiliation(s)
- Danmeng Luo
- Department of Medicinal Chemistry, University of Florida , Gainesville, Florida 32610, United States.,Center for Natural Products, Drug Discovery and Development (CNPD3), University of Florida , Gainesville, Florida 32610, United States
| | - Qi-Yin Chen
- Department of Medicinal Chemistry, University of Florida , Gainesville, Florida 32610, United States.,Center for Natural Products, Drug Discovery and Development (CNPD3), University of Florida , Gainesville, Florida 32610, United States
| | - Hendrik Luesch
- Department of Medicinal Chemistry, University of Florida , Gainesville, Florida 32610, United States.,Center for Natural Products, Drug Discovery and Development (CNPD3), University of Florida , Gainesville, Florida 32610, United States
| |
Collapse
|
59
|
Ranasinghe SL, Fischer K, Zhang W, Gobert GN, McManus DP. Cloning and Characterization of Two Potent Kunitz Type Protease Inhibitors from Echinococcus granulosus. PLoS Negl Trop Dis 2015; 9:e0004268. [PMID: 26645974 PMCID: PMC4672886 DOI: 10.1371/journal.pntd.0004268] [Citation(s) in RCA: 32] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/18/2015] [Accepted: 11/06/2015] [Indexed: 11/18/2022] Open
Abstract
The tapeworm Echinococcus granulosus is responsible for cystic echinococcosis (CE), a cosmopolitan disease which imposes a significant burden on the health and economy of affected communities. Little is known about the molecular mechanisms whereby E. granulosus is able to survive in the hostile mammalian host environment, avoiding attack by host enzymes and evading immune responses, but protease inhibitors released by the parasite are likely implicated. We identified two nucleotide sequences corresponding to secreted single domain Kunitz type protease inhibitors (EgKIs) in the E. granulosus genome, and their cDNAs were cloned, bacterially expressed and purified. EgKI-1 is highly expressed in the oncosphere (egg) stage and is a potent chymotrypsin and neutrophil elastase inhibitor that binds calcium and reduced neutrophil infiltration in a local inflammation model. EgKI-2 is highly expressed in adult worms and is a potent inhibitor of trypsin. As powerful inhibitors of mammalian intestinal proteases, the EgKIs may play a pivotal protective role in preventing proteolytic enzyme attack thereby ensuring survival of E. granulosus within its mammalian hosts. EgKI-1 may also be involved in the oncosphere in host immune evasion by inhibiting neutrophil elastase and cathepsin G once this stage is exposed to the mammalian blood system. In light of their key roles in protecting E. granulosus from host enzymatic attack, the EgKI proteins represent potential intervention targets to control CE. This is important as new public health measures against CE are required, given the inefficiencies of available drugs and the current difficulties in its treatment and control. In addition, being a small sized highly potent serine protease inhibitor, and an inhibitor of neutrophil chemotaxis, EgKI-1 may have clinical potential as a novel anti-inflammatory therapeutic.
Collapse
Affiliation(s)
- Shiwanthi L. Ranasinghe
- Molecular Parasitology Laboratory, QIMR Berghofer Medical Research Institute, Herston, Queensland, Australia
- School of Public Health, The University of Queensland, Herston, Queensland, Australia
| | - Katja Fischer
- Molecular Parasitology Laboratory, QIMR Berghofer Medical Research Institute, Herston, Queensland, Australia
| | - Wenbao Zhang
- Molecular Parasitology Laboratory, QIMR Berghofer Medical Research Institute, Herston, Queensland, Australia
- Department of Biochemistry, Xinjiang Medical University, Urumqi, Xinjiang, China
- Clinical Medical Research Institute, The First Affiliated Hospital of Xinjiang Medical University, Urumqi, Xinjiang, China
| | - Geoffrey N. Gobert
- Molecular Parasitology Laboratory, QIMR Berghofer Medical Research Institute, Herston, Queensland, Australia
| | - Donald P. McManus
- Molecular Parasitology Laboratory, QIMR Berghofer Medical Research Institute, Herston, Queensland, Australia
| |
Collapse
|
60
|
Hofbauer S, Brito JA, Mulchande J, Nogly P, Pessanha M, Moreira R, Archer M. Stabilization of porcine pancreatic elastase crystals by glutaraldehyde cross-linking. ACTA CRYSTALLOGRAPHICA SECTION F-STRUCTURAL BIOLOGY COMMUNICATIONS 2015; 71:1346-51. [PMID: 26457529 DOI: 10.1107/s2053230x15017045] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/03/2015] [Accepted: 09/11/2015] [Indexed: 11/10/2022]
Abstract
Elastase is a serine protease from the chymotrypsin family of enzymes with the ability to degrade elastin, an important component of connective tissues. Excessive elastin proteolysis leads to a number of pathological diseases. Porcine pancreatic elastase (PPE) is often used for drug development as a model for human leukocyte elastase (HLE), with which it shares high sequence identity. Crystals of PPE were grown overnight using sodium sulfate and sodium acetate at acidic pH. Cross-linking the crystals with glutaraldehyde was needed to resist the soaking procedure with a diethyl N-(methyl)pyridinyl-substituted oxo-β-lactam inhibitor. Crystals of PPE bound to the inhibitor belonged to the orthorhombic space group P2₁2₁2₁, with unit-cell parameters a = 51.0, b = 58.3, c = 74.9 Å, and diffracted to 1.8 Å resolution using an in-house X-ray source.
Collapse
Affiliation(s)
- Stefan Hofbauer
- Instituto de Tecnologia Química e Biológica - António Xavier, Universidade Nova de Lisboa, Avenida da República, EAN, 2780-157 Oeiras, Portugal
| | - José A Brito
- Instituto de Tecnologia Química e Biológica - António Xavier, Universidade Nova de Lisboa, Avenida da República, EAN, 2780-157 Oeiras, Portugal
| | - Jalmira Mulchande
- Research Institute for Medicines (i-Med.ULisboa), Faculdade de Farmácia, Universidade de Lisboa, Avenida Professor Gama Pinto, 1649-003 Lisboa, Portugal
| | - Przemyslaw Nogly
- Instituto de Tecnologia Química e Biológica - António Xavier, Universidade Nova de Lisboa, Avenida da República, EAN, 2780-157 Oeiras, Portugal
| | - Miguel Pessanha
- Instituto de Tecnologia Química e Biológica - António Xavier, Universidade Nova de Lisboa, Avenida da República, EAN, 2780-157 Oeiras, Portugal
| | - Rui Moreira
- Research Institute for Medicines (i-Med.ULisboa), Faculdade de Farmácia, Universidade de Lisboa, Avenida Professor Gama Pinto, 1649-003 Lisboa, Portugal
| | - Margarida Archer
- Instituto de Tecnologia Química e Biológica - António Xavier, Universidade Nova de Lisboa, Avenida da República, EAN, 2780-157 Oeiras, Portugal
| |
Collapse
|
61
|
von Nussbaum F, Li VMJ. Neutrophil elastase inhibitors for the treatment of (cardio)pulmonary diseases: Into clinical testing with pre-adaptive pharmacophores. Bioorg Med Chem Lett 2015; 25:4370-81. [PMID: 26358162 DOI: 10.1016/j.bmcl.2015.08.049] [Citation(s) in RCA: 76] [Impact Index Per Article: 8.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/01/2015] [Revised: 08/14/2015] [Accepted: 08/20/2015] [Indexed: 02/04/2023]
Abstract
Alpha-1 antitrypsin deficiency is linked with an increased risk of suffering from lung emphysema. This discovery from the 1960s led to the development of the protease-antiprotease (im)balance hypothesis: Overshooting protease concentrations, especially high levels of elastase were deemed to have an destructive effect on lung tissue. Consequently, it was postulated that efficient elastase inhibitors could alleviate the situation in patients. However, despite intensive drug discovery efforts, even five decades later, no neutrophil elastase inhibitors are available for a disease-modifying treatment of (cardio)pulmonary diseases such as chronic obstructive pulmonary disease. Here, we critically review the attempts to develop effective human neutrophil elastase inhibitors while strongly focussing on recent developments. On purpose and with perspective distortion we focus on recent developments. One aim of this review is to classify the known HNE inhibitors into several generations, according to their binding modes. In general, there seem to be three major challenges in the development of suitable elastase inhibitors: (1) assuring sufficient potency, (2) securing selectivity, and (3) achieving metabolic stability especially under pathophysiological conditions. Impressive achievements have been made since 2001 with the identification of potent nonreactive, reversible small molecule inhibitors. The most modern inhibitors bind HNE via an induced fit with a frozen bioactive conformation that leads to a significant boost in potency, selectivity, and stability ('pre-adaptive pharmacophores'). These 5th generation inhibitors might succeed in re-establishing the protease-antiprotease balance in patients for the first time.
Collapse
Affiliation(s)
| | - Volkhart M-J Li
- Bayer HealthCare AG, Lead Discovery Wuppertal, 42096 Wuppertal, Germany.
| |
Collapse
|
62
|
Gu C, Lewis RJ, Wells AS, Svensson PH, Hosagrahara VP, Johnsson E, Hallström G. Lipid Peroxide-Mediated Oxidative Rearrangement of the Pyrazinone Carboxamide Core of Neutrophil Elastase Inhibitor AZD9819 in Blood Plasma Samples. Drug Metab Dispos 2015. [PMID: 26203069 DOI: 10.1124/dmd.115.065136] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/03/2023] Open
Abstract
This study focused on the mechanistic interpretation of ex vivo oxidation of a candidate drug in blood plasma samples. An unexpected lipid peroxide-mediated epoxidation followed by a dramatic rearrangement led to production of a five-membered oxazole derivative from the original six-membered pyrazinone-carboxamide core of a human neutrophil elastase inhibitor, 6-(1-(4-cyanophenyl)-1H-pyrazol-5-yl)-N-ethyl-5-methyl-3-oxo-4-(3-(trifluoromethyl)phenyl)-3,4-dihydropyrazine-2-carboxamide (AZD9819). The rearranged oxidation product 2-(1-(4-cyanophenyl)-1H-pyrazol-5-yl)-5-(N-ethylacetamido)-N-(3-(trifluoromethyl)phenyl)oxazole-4-carboxamide was characterized by accurate-mass tandem mass spectrometry fragmentations, by two-dimensional NMR and X-ray crystallography of an authentic standard, and by incorporation of an (18)O atom from molecular (18)O2 to the location predicted by our proposed mechanism. The lipid peroxide-mediated oxidation was demonstrated by using human low-density lipoprotein (LDL) in pH 7.4 phosphate buffer and by inhibiting the oxidation with ascorbic acid or l-glutathione, two antioxidants effective in both plasma and the LDL incubation. A nucleophilic mechanism for the epoxidation of AZD9819 by lipid hydroperoxides explains the prevention of its ex vivo oxidation by acidification of the plasma samples. The discovery of the lipid peroxide-dependent oxidation of an analyte and the means of prevention could provide valuable information for biotransformation and bioanalysis.
Collapse
Affiliation(s)
- Chungang Gu
- AstraZeneca, R&D Boston, Waltham, Massachusetts (C.G., V.P.H.); AstraZeneca, R&D Mölndal, Mölndal, Sweden (R.J.L., E.J.); AstraZeneca, R&D Charnwood, Loughborough, United Kingdom (R.J.L., A.S.W.); AstraZeneca, R&D Södertälje, Södertälje, Sweden (P.H.S); AstraZeneca, R&D Wilmington, Wilmington, Delaware (C.G.); AstraZeneca, R&D Lund, Lund, Sweden (E.J., G.H.); SP Process Development, Södertälje, Sweden (P.H.S.); and Applied Physical Chemistry, Royal Institute of Technology, Stockholm, Sweden (P.H.S.)
| | - Richard J Lewis
- AstraZeneca, R&D Boston, Waltham, Massachusetts (C.G., V.P.H.); AstraZeneca, R&D Mölndal, Mölndal, Sweden (R.J.L., E.J.); AstraZeneca, R&D Charnwood, Loughborough, United Kingdom (R.J.L., A.S.W.); AstraZeneca, R&D Södertälje, Södertälje, Sweden (P.H.S); AstraZeneca, R&D Wilmington, Wilmington, Delaware (C.G.); AstraZeneca, R&D Lund, Lund, Sweden (E.J., G.H.); SP Process Development, Södertälje, Sweden (P.H.S.); and Applied Physical Chemistry, Royal Institute of Technology, Stockholm, Sweden (P.H.S.)
| | - Andrew S Wells
- AstraZeneca, R&D Boston, Waltham, Massachusetts (C.G., V.P.H.); AstraZeneca, R&D Mölndal, Mölndal, Sweden (R.J.L., E.J.); AstraZeneca, R&D Charnwood, Loughborough, United Kingdom (R.J.L., A.S.W.); AstraZeneca, R&D Södertälje, Södertälje, Sweden (P.H.S); AstraZeneca, R&D Wilmington, Wilmington, Delaware (C.G.); AstraZeneca, R&D Lund, Lund, Sweden (E.J., G.H.); SP Process Development, Södertälje, Sweden (P.H.S.); and Applied Physical Chemistry, Royal Institute of Technology, Stockholm, Sweden (P.H.S.)
| | - Per H Svensson
- AstraZeneca, R&D Boston, Waltham, Massachusetts (C.G., V.P.H.); AstraZeneca, R&D Mölndal, Mölndal, Sweden (R.J.L., E.J.); AstraZeneca, R&D Charnwood, Loughborough, United Kingdom (R.J.L., A.S.W.); AstraZeneca, R&D Södertälje, Södertälje, Sweden (P.H.S); AstraZeneca, R&D Wilmington, Wilmington, Delaware (C.G.); AstraZeneca, R&D Lund, Lund, Sweden (E.J., G.H.); SP Process Development, Södertälje, Sweden (P.H.S.); and Applied Physical Chemistry, Royal Institute of Technology, Stockholm, Sweden (P.H.S.)
| | - Vinayak P Hosagrahara
- AstraZeneca, R&D Boston, Waltham, Massachusetts (C.G., V.P.H.); AstraZeneca, R&D Mölndal, Mölndal, Sweden (R.J.L., E.J.); AstraZeneca, R&D Charnwood, Loughborough, United Kingdom (R.J.L., A.S.W.); AstraZeneca, R&D Södertälje, Södertälje, Sweden (P.H.S); AstraZeneca, R&D Wilmington, Wilmington, Delaware (C.G.); AstraZeneca, R&D Lund, Lund, Sweden (E.J., G.H.); SP Process Development, Södertälje, Sweden (P.H.S.); and Applied Physical Chemistry, Royal Institute of Technology, Stockholm, Sweden (P.H.S.)
| | - Eskil Johnsson
- AstraZeneca, R&D Boston, Waltham, Massachusetts (C.G., V.P.H.); AstraZeneca, R&D Mölndal, Mölndal, Sweden (R.J.L., E.J.); AstraZeneca, R&D Charnwood, Loughborough, United Kingdom (R.J.L., A.S.W.); AstraZeneca, R&D Södertälje, Södertälje, Sweden (P.H.S); AstraZeneca, R&D Wilmington, Wilmington, Delaware (C.G.); AstraZeneca, R&D Lund, Lund, Sweden (E.J., G.H.); SP Process Development, Södertälje, Sweden (P.H.S.); and Applied Physical Chemistry, Royal Institute of Technology, Stockholm, Sweden (P.H.S.)
| | - Gösta Hallström
- AstraZeneca, R&D Boston, Waltham, Massachusetts (C.G., V.P.H.); AstraZeneca, R&D Mölndal, Mölndal, Sweden (R.J.L., E.J.); AstraZeneca, R&D Charnwood, Loughborough, United Kingdom (R.J.L., A.S.W.); AstraZeneca, R&D Södertälje, Södertälje, Sweden (P.H.S); AstraZeneca, R&D Wilmington, Wilmington, Delaware (C.G.); AstraZeneca, R&D Lund, Lund, Sweden (E.J., G.H.); SP Process Development, Södertälje, Sweden (P.H.S.); and Applied Physical Chemistry, Royal Institute of Technology, Stockholm, Sweden (P.H.S.)
| |
Collapse
|
63
|
Nayak RC, Trump LR, Aronow BJ, Myers K, Mehta P, Kalfa T, Wellendorf AM, Valencia CA, Paddison PJ, Horwitz MS, Grimes HL, Lutzko C, Cancelas JA. Pathogenesis of ELANE-mutant severe neutropenia revealed by induced pluripotent stem cells. J Clin Invest 2015; 125:3103-16. [PMID: 26193632 DOI: 10.1172/jci80924] [Citation(s) in RCA: 53] [Impact Index Per Article: 5.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/12/2015] [Accepted: 06/05/2015] [Indexed: 12/27/2022] Open
Abstract
Severe congenital neutropenia (SCN) is often associated with inherited heterozygous point mutations in ELANE, which encodes neutrophil elastase (NE). However, a lack of appropriate models to recapitulate SCN has substantially hampered the understanding of the genetic etiology and pathobiology of this disease. To this end, we generated both normal and SCN patient-derived induced pluripotent stem cells (iPSCs), and performed genome editing and differentiation protocols that recapitulate the major features of granulopoiesis. Pathogenesis of ELANE point mutations was the result of promyelocyte death and differentiation arrest, and was associated with NE mislocalization and activation of the unfolded protein response/ER stress (UPR/ER stress). Similarly, high-dose G-CSF (or downstream signaling through AKT/BCL2) rescues the dysgranulopoietic defect in SCN patient-derived iPSCs through C/EBPβ-dependent emergency granulopoiesis. In contrast, sivelestat, an NE-specific small-molecule inhibitor, corrected dysgranulopoiesis by restoring normal intracellular NE localization in primary granules; ameliorating UPR/ER stress; increasing expression of CEBPA, but not CEBPB; and promoting promyelocyte survival and differentiation. Together, these data suggest that SCN disease pathogenesis includes NE mislocalization, which in turn triggers dysfunctional survival signaling and UPR/ER stress. This paradigm has the potential to be clinically exploited to achieve therapeutic responses using lower doses of G-CSF combined with targeting to correct NE mislocalization.
Collapse
|
64
|
von Nussbaum F, Li VMJ, Allerheiligen S, Anlauf S, Bärfacker L, Bechem M, Delbeck M, Fitzgerald MF, Gerisch M, Gielen-Haertwig H, Haning H, Karthaus D, Lang D, Lustig K, Meibom D, Mittendorf J, Rosentreter U, Schäfer M, Schäfer S, Schamberger J, Telan LA, Tersteegen A. Freezing the Bioactive Conformation to Boost Potency: The Identification of BAY 85-8501, a Selective and Potent Inhibitor of Human Neutrophil Elastase for Pulmonary Diseases. ChemMedChem 2015; 10:1163-73. [PMID: 26083237 PMCID: PMC4515084 DOI: 10.1002/cmdc.201500131] [Citation(s) in RCA: 53] [Impact Index Per Article: 5.9] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/26/2015] [Indexed: 12/01/2022]
Abstract
Human neutrophil elastase (HNE) is a key protease for matrix degradation. High HNE activity is observed in inflammatory diseases. Accordingly, HNE is a potential target for the treatment of pulmonary diseases such as chronic obstructive pulmonary disease (COPD), acute lung injury (ALI), acute respiratory distress syndrome (ARDS), bronchiectasis (BE), and pulmonary hypertension (PH). HNE inhibitors should reestablish the protease-anti-protease balance. By means of medicinal chemistry a novel dihydropyrimidinone lead-structure class was identified. Further chemical optimization yielded orally active compounds with favorable pharmacokinetics such as the chemical probe BAY-678. While maintaining outstanding target selectivity, picomolar potency was achieved by locking the bioactive conformation of these inhibitors with a strategically positioned methyl sulfone substituent. An induced-fit binding mode allowed tight interactions with the S2 and S1 pockets of HNE. BAY 85-8501 ((4S)-4-[4-cyano-2-(methylsulfonyl)phenyl]-3,6-dimethyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2,3,4-tetrahydropyrimidine-5-carbonitrile) was shown to be efficacious in a rodent animal model related to ALI. BAY 85-8501 is currently being tested in clinical studies for the treatment of pulmonary diseases.
Collapse
Affiliation(s)
- Franz von Nussbaum
- Medicinal Chemistry Berlin, Bayer HealthCare AG, 13353 Berlin (Germany).
| | - Volkhart M-J Li
- Lead Discovery Wuppertal, Bayer HealthCare AG, 42096 Wuppertal (Germany).
| | - Swen Allerheiligen
- Medicinal Chemistry Wuppertal, Bayer HealthCare AG, 42096 Wuppertal (Germany)
| | - Sonja Anlauf
- Medicinal Chemistry Wuppertal, Bayer HealthCare AG, 42096 Wuppertal (Germany)
| | - Lars Bärfacker
- Medicinal Chemistry Wuppertal, Bayer HealthCare AG, 42096 Wuppertal (Germany)
| | - Martin Bechem
- Department of Cardiology Research Wuppertal, Bayer HealthCare AG, 42096 Wuppertal (Germany)
| | - Martina Delbeck
- Department of Cardiology Research Wuppertal, Bayer HealthCare AG, 42096 Wuppertal (Germany)
| | | | - Michael Gerisch
- DMPK Wuppertal, Bayer HealthCare AG, 42096 Wuppertal (Germany)
| | | | - Helmut Haning
- Medicinal Chemistry Wuppertal, Bayer HealthCare AG, 42096 Wuppertal (Germany)
| | - Dagmar Karthaus
- Medicinal Chemistry Wuppertal, Bayer HealthCare AG, 42096 Wuppertal (Germany)
| | - Dieter Lang
- DMPK Wuppertal, Bayer HealthCare AG, 42096 Wuppertal (Germany)
| | - Klemens Lustig
- DMPK Wuppertal, Bayer HealthCare AG, 42096 Wuppertal (Germany)
| | - Daniel Meibom
- Medicinal Chemistry Wuppertal, Bayer HealthCare AG, 42096 Wuppertal (Germany)
| | - Joachim Mittendorf
- Medicinal Chemistry Wuppertal, Bayer HealthCare AG, 42096 Wuppertal (Germany)
| | - Ulrich Rosentreter
- Medicinal Chemistry Wuppertal, Bayer HealthCare AG, 42096 Wuppertal (Germany)
| | - Martina Schäfer
- Lead Discovery, Structural Biology Berlin, Bayer HealthCare AG, 13353 Berlin (Germany)
| | - Stefan Schäfer
- Department of Cardiology Research Wuppertal, Bayer HealthCare AG, 42096 Wuppertal (Germany)
| | - Jens Schamberger
- Medicinal Chemistry Wuppertal, Bayer HealthCare AG, 42096 Wuppertal (Germany)
| | - Leila A Telan
- Medicinal Chemistry Wuppertal, Bayer HealthCare AG, 42096 Wuppertal (Germany)
| | - Adrian Tersteegen
- Lead Discovery Wuppertal, Bayer HealthCare AG, 42096 Wuppertal (Germany)
| |
Collapse
|
65
|
Areias LRP, Ruivo EFP, Gonçalves LM, Duarte MT, André V, Moreira R, Lucas SD, Guedes RC. A unified approach toward the rational design of selective low nanomolar human neutrophil elastase inhibitors. RSC Adv 2015. [DOI: 10.1039/c5ra07783d] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/20/2023] Open
Abstract
A computer-aided campaign boosted the discovery of potent human neutrophil elastase (HNE) inhibitors.
Collapse
Affiliation(s)
- L. R. P. Areias
- Research Institute for Medicines (iMed.ULisboa)
- Faculty of Pharmacy
- Universidade de Lisboa
- 1649-003 Lisbon
- Portugal
| | - E. F. P. Ruivo
- Research Institute for Medicines (iMed.ULisboa)
- Faculty of Pharmacy
- Universidade de Lisboa
- 1649-003 Lisbon
- Portugal
| | - L. M. Gonçalves
- Research Institute for Medicines (iMed.ULisboa)
- Faculty of Pharmacy
- Universidade de Lisboa
- 1649-003 Lisbon
- Portugal
| | - M. T. Duarte
- Centro de Química Estrutural
- Instituto Superior Técnico
- Universidade de Lisboa
- 1049-001 Lisboa
- Portugal
| | - V. André
- Centro de Química Estrutural
- Instituto Superior Técnico
- Universidade de Lisboa
- 1049-001 Lisboa
- Portugal
| | - R. Moreira
- Research Institute for Medicines (iMed.ULisboa)
- Faculty of Pharmacy
- Universidade de Lisboa
- 1649-003 Lisbon
- Portugal
| | - S. D. Lucas
- Research Institute for Medicines (iMed.ULisboa)
- Faculty of Pharmacy
- Universidade de Lisboa
- 1649-003 Lisbon
- Portugal
| | - R. C. Guedes
- Research Institute for Medicines (iMed.ULisboa)
- Faculty of Pharmacy
- Universidade de Lisboa
- 1649-003 Lisbon
- Portugal
| |
Collapse
|
66
|
Lucas SD, Carrasco MP, Gonçalves LM, Moreira R, Guedes RC. Discovery of C-shaped aurone human neutrophil elastase inhibitors. MEDCHEMCOMM 2015. [DOI: 10.1039/c5md00164a] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
Aurones were discovered as sub-micromolar HNE inhibitors. The activity is rationalized by a C-shape conformation that allows tight binding to HNE S1 and S2 pockets.
Collapse
Affiliation(s)
- S. D. Lucas
- Research Institute for Medicines (iMed.ULisboa)
- Faculty of Pharmacy
- Universidade de Lisboa
- 1649-003 Lisboa
- Portugal
| | - M. P. Carrasco
- Research Institute for Medicines (iMed.ULisboa)
- Faculty of Pharmacy
- Universidade de Lisboa
- 1649-003 Lisboa
- Portugal
| | - L. M. Gonçalves
- Research Institute for Medicines (iMed.ULisboa)
- Faculty of Pharmacy
- Universidade de Lisboa
- 1649-003 Lisboa
- Portugal
| | - R. Moreira
- Research Institute for Medicines (iMed.ULisboa)
- Faculty of Pharmacy
- Universidade de Lisboa
- 1649-003 Lisboa
- Portugal
| | - R. C. Guedes
- Research Institute for Medicines (iMed.ULisboa)
- Faculty of Pharmacy
- Universidade de Lisboa
- 1649-003 Lisboa
- Portugal
| |
Collapse
|
67
|
Abdel-Magid AF. Neutrophil elastase inhibitors as potential anti-inflammatory therapies. ACS Med Chem Lett 2014; 5:1182-3. [PMID: 25408826 DOI: 10.1021/ml500346u] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/27/2014] [Indexed: 11/28/2022] Open
|
68
|
Budnjo A, Narawane S, Grauffel C, Schillinger AS, Fossen T, Reuter N, Haug BE. Reversible ketomethylene-based inhibitors of human neutrophil proteinase 3. J Med Chem 2014; 57:9396-408. [PMID: 25365140 DOI: 10.1021/jm500782s] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/14/2023]
Abstract
Neutrophil serine proteases, proteinase 3 (PR3) and human neutrophil elastase (HNE), are considered as targets for chronic inflammatory diseases. Despite sharing high sequence similarity, the two enzymes have different substrate specificities and functions. While a plethora of HNE inhibitors exist, PR3 specific inhibitors are still in their infancy. We have designed ketomethylene-based inhibitors for PR3 that show low micromolar IC50 values. Their synthesis was made possible by amending a previously reported synthesis of ketomethylene dipeptide isosteres to allow for the preparation of derivatives suitable for solid phase peptide synthesis. The best inhibitor (Abz-VADnV[Ψ](COCH2)ADYQ-EDDnp) was found to be selective for PR3 over HNE and to display a competitive and reversible inhibition mechanism. Molecular dynamics simulations show that the interactions between enzyme and ketomethylene-containing inhibitors are similar to those with the corresponding substrates. We also confirm that N- and C-terminal FRET groups are important for securing high inhibitory potency toward PR3.
Collapse
Affiliation(s)
- Adnan Budnjo
- Department of Chemistry and Centre for Pharmacy, University of Bergen , Allégaten 41, 5007 Bergen, Norway
| | | | | | | | | | | | | |
Collapse
|
69
|
Inhibition of myeloperoxidase: evaluation of 2H-indazoles and 1H-indazolones. Bioorg Med Chem 2014; 22:6422-9. [PMID: 25438766 DOI: 10.1016/j.bmc.2014.09.044] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/17/2014] [Revised: 09/13/2014] [Accepted: 09/20/2014] [Indexed: 01/05/2023]
Abstract
Myeloperoxidase (MPO) produces hypohalous acids as a key component of the innate immune response; however, release of these acids extracellularly results in inflammatory cell and tissue damage. The two-step, one-pot Davis-Beirut reaction was used to synthesize a library of 2H-indazoles and 1H-indazolones as putative inhibitors of MPO. A structure-activity relationship study was undertaken wherein compounds were evaluated utilizing taurine-chloramine and MPO-mediated H2O2 consumption assays. Docking studies as well as toxicophore and Lipinski analyses were performed. Fourteen compounds were found to be potent inhibitors with IC50 values <1μM, suggesting these compounds could be considered as potential modulators of pro-oxidative tissue injury pertubated by the inflammatory MPO/H2O2/HOCl/HOBr system.
Collapse
|
70
|
Abstract
PURPOSE OF REVIEW To review progress over the past 5 years in relating extracellular proteinases to plaque rupture, the cause of most myocardial infarctions, and consider the most promising prospects for developing related treatments. RECENT FINDINGS Cysteinyl cathepsins have been implicated in multiple macrophage functions that could promote plaque rupture. Cathepsin K is an attractive target because it is a collagenase and selective inhibitors are already being used in phase III clinical trials. Several serine proteinases clearly influence vascular remodelling and atherogenesis but important, unrelated actions limit their value as therapeutic targets. Among the metalloproteinases, new evidence supports roles for A Disintigrin and Metalloproteinases (ADAMs), including ADAM-10, ADAM-17 and ADAM-33, which suggest that selective inhibitors might be effective treatments. For ADAMs with ThromboSpondin domains (ADAMTSs), there are biological and genome-wide association data linking ADAMTS-7 to incidence of coronary heart disease but not increased risk of myocardial infarctions. In the case of matrix metalloproteinases (MMPs), selective inhibitors of MMP-12 and MMP-13 are available and may be appropriate for development as therapies. Novel targets, including MMP-8, MMP-10, MMP-14, MMP-19, MMP-25 and MMP-28, are also being considered. SUMMARY New opportunities exist to exploit proteinases as therapeutic targets in plaque rupture.
Collapse
Affiliation(s)
- Andrew C Newby
- University of Bristol and Bristol Heart Institute, Bristol, UK
| |
Collapse
|
71
|
Montalbano F, Cal PMSD, Carvalho MABR, Gonçalves LM, Lucas SD, Guedes RC, Veiros LF, Moreira R, Gois PMP. Discovery of new heterocycles with activity against human neutrophile elastase based on a boron promoted one-pot assembly reaction. Org Biomol Chem 2014; 11:4465-72. [PMID: 23715243 DOI: 10.1039/c3ob40614h] [Citation(s) in RCA: 28] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/15/2023]
Abstract
Herein we demonstrate for the first time that a boron promoted one-pot assembly reaction may be used to discover novel enzyme inhibitors. Inhibitors for HNE were simply assembled in excellent yields, high diastereoselectivities and IC50 up to 1.10 μM, based on components like salicylaldehyde, aryl boronic acids and amino acids. The combination of synthetic, biochemical, analytical and theoretical studies allowed the identification of the 4-methoxy or the 4-diethyl amino substituent of the salicylaldehyde as the most important recognition moiety and the imine alkylation, lactone ring opening as key events in the mechanism of inhibition.
Collapse
Affiliation(s)
- Francesco Montalbano
- Research Institute for Medicines and Pharmaceutical Sciences (iMed.UL), Faculty of Pharmacy, University of Lisbon, Av. Prof. Gama Pinto, 1649-003 Lisbon, Portugal
| | | | | | | | | | | | | | | | | |
Collapse
|
72
|
Lucas SD, Gonçalves LM, Carvalho LAR, Correia HF, Da Costa EMR, Guedes RA, Moreira R, Guedes RC. Optimization of O3-Acyl Kojic Acid Derivatives as Potent and Selective Human Neutrophil Elastase Inhibitors. J Med Chem 2013; 56:9802-6. [DOI: 10.1021/jm4011725] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Affiliation(s)
- Susana D. Lucas
- Instituto de Investigação do Medicamento
(iMed.ULisboa), Faculdade de Farmácia, Universidade de Lisboa, Av. Prof. Gama Pinto, 1649-003 Lisboa, Portugal
| | - Lídia M. Gonçalves
- Instituto de Investigação do Medicamento
(iMed.ULisboa), Faculdade de Farmácia, Universidade de Lisboa, Av. Prof. Gama Pinto, 1649-003 Lisboa, Portugal
| | - Luís A. R. Carvalho
- Instituto de Investigação do Medicamento
(iMed.ULisboa), Faculdade de Farmácia, Universidade de Lisboa, Av. Prof. Gama Pinto, 1649-003 Lisboa, Portugal
| | - Henrique F. Correia
- Instituto de Investigação do Medicamento
(iMed.ULisboa), Faculdade de Farmácia, Universidade de Lisboa, Av. Prof. Gama Pinto, 1649-003 Lisboa, Portugal
| | - Eduardo M. R. Da Costa
- Instituto de Investigação do Medicamento
(iMed.ULisboa), Faculdade de Farmácia, Universidade de Lisboa, Av. Prof. Gama Pinto, 1649-003 Lisboa, Portugal
| | - Romina A. Guedes
- Instituto de Investigação do Medicamento
(iMed.ULisboa), Faculdade de Farmácia, Universidade de Lisboa, Av. Prof. Gama Pinto, 1649-003 Lisboa, Portugal
| | - Rui Moreira
- Instituto de Investigação do Medicamento
(iMed.ULisboa), Faculdade de Farmácia, Universidade de Lisboa, Av. Prof. Gama Pinto, 1649-003 Lisboa, Portugal
| | - Rita C. Guedes
- Instituto de Investigação do Medicamento
(iMed.ULisboa), Faculdade de Farmácia, Universidade de Lisboa, Av. Prof. Gama Pinto, 1649-003 Lisboa, Portugal
| |
Collapse
|
73
|
Zheng Z, Zhang S, Lu X, Ma Y, Fan Y, Shi Y, Dong A, Duan B. Trivaric acid, a potent depside human leukocyte elastase inhibitor. Biol Pharm Bull 2012; 35:2247-51. [PMID: 23006633 DOI: 10.1248/bpb.b12-00642] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
Human leukocyte elastase (HLE) is a serine protease implicated in several inflammatory diseases, and represents a major target for anti-inflammatory drug development. In the present study, nordivaricatic acid (1), divarinyl divarate (2), and trivaric acid (3), three depsides isolated from the culture of a soil derived fungal strain were identified as inhibitors of HLE. Two didepsides 1 and 2 showed low inhibitory activity. In contrast, trivaric acid, a para-tridepside, exhibited highly potent inhibitory activity with an IC(50) value of 1.8 µM and a K(i) of 0.6 µM. Kinetic investigations with trivaric acid showed that this inhibition is reversible, competitive pattern. Further studies on the selectivity of three depsides toward serine proteases showed that they did not inhibit chymotrypsin, trypsin and thrombin even at 150 µM.
Collapse
Affiliation(s)
- Zhihui Zheng
- New Drug Research & Development Center, North China Pharmaceutical Group Corporation, No. 388 Heping East Road, Shijiazhuang 050015, Hebei, China
| | | | | | | | | | | | | | | |
Collapse
|
74
|
Madsen JLH, Andersen TL, Santamaria S, Nagase H, Enghild JJ, Skrydstrup T. Synthesis and Evaluation of Silanediols as Highly Selective Uncompetitive Inhibitors of Human Neutrophil Elastase. J Med Chem 2012; 55:7900-8. [DOI: 10.1021/jm301000k] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Affiliation(s)
- Julie L. H. Madsen
- Center for Insoluble Protein
Structures, Department of Chemistry, and Interdisciplinary Nanoscience
Center, Aarhus University, Langelandsgade
140, 8000 Aarhus C, Denmark
| | - Thomas L. Andersen
- Center for Insoluble Protein
Structures, Department of Chemistry, and Interdisciplinary Nanoscience
Center, Aarhus University, Langelandsgade
140, 8000 Aarhus C, Denmark
| | - Salvatore Santamaria
- Faculty of Medicine, Imperial College London, 65 Aspenlea Road, London W6
8LH, U.K
- The Kennedy Institute
of Rheumatology,
Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal
Sciences, University of Oxford, 65 Aspenlea
Road, London W6 8LH, U.K
| | - Hideaki Nagase
- Faculty of Medicine, Imperial College London, 65 Aspenlea Road, London W6
8LH, U.K
- The Kennedy Institute
of Rheumatology,
Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal
Sciences, University of Oxford, 65 Aspenlea
Road, London W6 8LH, U.K
| | - Jan J. Enghild
- Center for Insoluble Protein
Structures, Department of Molecular Biology and Genetics, and Interdisciplinary
Nanoscience Center, Aarhus University,
Gustav Wieds Vej 10, 8000 Aarhus C, Denmark
| | - Troels Skrydstrup
- Center for Insoluble Protein
Structures, Department of Chemistry, and Interdisciplinary Nanoscience
Center, Aarhus University, Langelandsgade
140, 8000 Aarhus C, Denmark
| |
Collapse
|
75
|
N-Acyl and N-sulfonyloxazolidine-2,4-diones are pseudo-irreversible inhibitors of serine proteases. Bioorg Med Chem Lett 2012; 22:3993-7. [PMID: 22595175 DOI: 10.1016/j.bmcl.2012.04.093] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/23/2011] [Revised: 04/19/2012] [Accepted: 04/20/2012] [Indexed: 11/24/2022]
Abstract
The synthesis, inhibitory activity and mode of action of oxazolidine-2,4-diones against porcine pancreatic elastase, here used as a model for human neutrophil elastase, are reported. The nature of N-substitution at the oxazolidine-2,4-dione scaffold has large effect on the inhibitory potency against elastase. N-Acyl and N-sulfonyloxazolidine-2,4-diones emerged as potent pseudo-irreversible inhibitors, displaying high second-order rate constants for PPE inactivation. The title compounds were also shown to be potent inhibitors of human neutrophil elastase (HNE) and proteinase-3, and weak inhibitors of human cathepsin G. The results herein presented show that the oxazolidine-2,4-diones represent a new promising class of serine protease inhibitors.
Collapse
|
76
|
Lucas SD, Gonçalves LM, Cardote TAF, Correia HF, Moreira R, Guedes RC. Structure based virtual screening for discovery of novel human neutrophil elastase inhibitors. MEDCHEMCOMM 2012. [DOI: 10.1039/c2md20090b] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
|